MEDIA RELEASE
For immediate release
Product
EKF Diagnostics Holdings plc
Martyn Lewis
t: +44 (0)29 20 710570
e: martynlewis@ekfdiagnostics.com
w: www.ekfdiagnostics.com
Alto Marketing Limited
Sarah Perceval
t: +44 (0)1489 557672 e: sarahp@alto-marketing.com
Twitter: @AltoMarketing
w: www.alto-marketing.com
Enquiries
Media enquiries
Ref
1416EKF REPLACEMENT
Release Status
EKF Diagnostics launches POC hemoglobin analyzer at Medica 2014
DiaSpect Tm – immediate hemoglobin results from a hand-held analyzer
Please contact sarahp@alto-marketing.com for a high resolution image.
Cardiff, UK – 17th November 2014 – EKF Diagnostics, the global diagnostics
company, has introduced the DiaSpect TM point of care (POC) hemoglobin analyzer at
Medica 2014, 12-15th November, Düsseldorf, Germany. Alongside this new product,
EKF exhibited a new version of its Hemo Control hemoglobin analyzer, the industryleading Biosen glucose and lactate analyzer, as well as previewing SensPoint, a new
lactate analyzer designed for use in professional medical settings.
Immediate hemoglobin results
The new DiaSpect Tm hemoglobin analyzer is a palm-sized point of care analyzer that
is fast, easy to use and reliable in all climate conditions as it combines laboratory
quality performance with unmatched measurement speed and extensive battery life.
In addition to its accuracy of result, DiaSpect Tm is extremely robust since it has no
moving parts. Furthermore it utilizes reagent-free microcuvettes which are unaffected
MEDIA RELEASE
by humidity, unlike reagent-based systems. These plexiglass microcuvettes also have a
long shelf-life of 2.5 years with no need for refrigeration as they can be stored from 0°
to 50°C. DiaSpect Tm is portable and lightweight at just 185g and has an extremely
long battery life of 40 days of continuous use, or 10,000 tests, due to its integrated
rechargeable lithium-ion battery.
DiaSpect Tm is factory calibrated against the HiCN reference method in accordance
with ICSH and requires no re-calibration or maintenance, as it undertakes an
automatic self-check between every measurement. Its ‘always on’ technology also
means the analyzer is permanently ready for use.
The user simply collects a capillary or venous blood sample of <10 µL in the
microcuvette and inserts it directly into the analyzer. Hemoglobin results are delivered
in just one second which can then be downloaded to a PC via USB or Bluetooth.
For more information on the DiaSpect Tm hemoglobin analyzer or EKF Diagnostics,
please visit www.ekfdiagnostics.com.
Editors’ notes
About EKF Diagnostics
www.ekfdiagnostics.com
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular,
Stanbio Laboratory, Separation Technology Inc, DiaSpect and Selah Genomics brands,
specializes in the development, production and worldwide distribution of point-of-care
blood analyzers for use in the detection and management of diabetes, anemia, lactate
and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics,
focuses on technology used within the development of companion diagnostics,
specifically within oncology. EKF products are sold in more than 100 countries around
the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class
diagnostic devices, as well as distributing rapid test kits for infectious diseases and
pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood
banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin,
hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory
(Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry
reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes
used in reagent development and also provides contract fermentation facilities.
Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular
and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF
Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes
from tiny biopsy and blood samples and has recently entered a partnership with the
MEDIA RELEASE
world renowned cancer research center at Massachusetts General Hospital, USA.
EKF Diagnostics’ strengths lie in its multi-national research and manufacturing
facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and
the UK, and a board led by some of world’s foremost authorities in medical diagnostics.